Atlas Trials

Neoadjuvant Adebrelimab With Dalpiciclib for Resectable Esophageal Squamous Cell Carcinomas

Clinical trial NCT06225921 · UNKNOWN

Trial details

NCT number
NCT06225921
Sponsor
West China Hospital
Status
UNKNOWN
Phase
Phase 1
Study type
INTERVENTIONAL
Esophageal Squamous Cell Carcinoma
Start date
2023-12-29
Primary completion
2025-01-15
Enrollment
6

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.